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Abstract 
 BACKGROUND: Causes of cerebral venous thrombosis (CVT) vary around the world. Oral con-
traceptive pills (OCP) are among the most frequent causes of cerebral venous thrombosis. 
 METHODS: Consecutive patients admitted with cerebral venous thrombosis in Ghaem hospit-
al, Mashhad during 2005-2008 were prospectively investigated. Diagnosis of cerebral venous 
thrombosis was made by corresponding results of MRI, and MRV or conventional angiography. 
All of the patients had a complete medical history, physical examination and underwent a stan-
dard battery of diagnostic investigations by stroke neurologists. 
 RESULTS: Sixty two patients (51 females, 11 males) with mean age of 32.3, ranged 18-62 years 
were admitted with cerebral venous thrombosis. Oral contraceptive pills consumption was 
found as risk factor in 56.8% of females with cerebral venous thrombosis. These females had 
used LD and HD types of oral contraceptive pills in 97% and 3% respectively. 41% of females 
with cerebral venous thrombosis; (21/51) were on short term oral contraceptive pills consump-
tion. In this latter group of females, Ramadan and Hadj religious months were the reason of us-
ing short term oral contraceptive pills in 86% and 5% respectively. 
 CONCLUSION: Short term oral contraceptive pills consumption is the most common cause of 
cerebral venous thrombosis in Iranian women. Programs for public awareness should be con-
ducted for reducing use of these pills in short term periods during Ramadan and Hadj months. 
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For a long time, cerebral venous thrombosis (CVT) 
was considered a rare disease confirmed by autopsy 
and associated with poor prognosis. In recent decades, 
the outlook for CVT has been dramatically improved 
by the use of Magnetic Resonance Imaging (MRI) and 
MR Venography leading to earlier diagnosis1. 
 Numerous conditions, both intracranial and extra-
cranial, have been implicated to cause CVT. When the 
thrombosis arises without an obvious cause, an exten-
sive and early workup is necessary because the underly-
ing disease may require special treatment.1 Even after 
full investigations, in 20-25 percent of cases, the cause 
remains uncertain.2 A diagnosis of idiopathic CVT 
should be made with caution, because other features of 
an underlying disease may only become evident on 
follow-up and after repeated investigations.1 Distribu-
tion of etiology of CVT varies around the world, e.g. 
Behcet disease accounted for about 25% of all CVT in 
Saudi Arabia.3 Puerperium remains a frequent cause of 
CVT, particularly in developing countries, which have 
more frequent prenatal infections and dehydration.4 
Among drugs associated with the occurrence of CVT, 
oral contraceptive pills (OCP) are by far the most 
common.1 This etiologic study investigates the causes 
of CVT in the east of Iran. 
Materials and Methods 
Consecutive patients with definite diagnosis of CVT, 
admitted in Ghaem hospital, Mashhad during 2005- 
2008 enrolled in a prospective observational study. 
Diagnosis of CVT was made by stroke neurologists. 
Confirmation of CVT is by corresponding both MRI 
and MRV. Thrombosis should be observed in T1 and 
T2 sequences of MRI with loss of signal void in the 
corresponding T2 sequence of the related sinus.5 De-
tection of cut-off point or filling defect in the related 
sinus in MRV is necessary for confirmation of CVT 
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diagnosis by MRI technology.5,6 Patients who were 
highly suspicious to CVT and had no MRI and MRV 
clues of CVT, underwent conventional angiography 
for detection of sinus filling defet.5,6 Detailed history 
of OCP consumption, its duration and type of OCP 
based on the estradiol component, were taken.7 
Short-term OCP consumption defined as using OCP 
in recent 3 months.7 Postpartum period defined as 3 
months after delivery.7,8 All of the patients underwent 
a standard battery of diagnostic investigation to de-
termine cause of CVT.8 The research was approved 
by ethics committee of Ghaem hospital. A signed 
informed consent was obtained from the patients or 
their first degree relatives. 
Results 
Sixty two patients (51 females, 11 males) with mean 
age of 32.3, ranged 18-62 years were admitted with 
CVT. Table 1 represents etiologies of CVT in our 
patients. Multiple causes were found in 29% of the 
patients. OCP consumption was found as risk factor 
in 56.8% of females (29/51) with CVT. This group of 
females had used LD (35 µg ethynil estradiol and 0.3 
µg nervogesterone) and HD (50 µg ethynil estradiol 
and 0.5 µg nervogestrone) types of OCP in 97% and 
3% respectively. Short term (less than 3 months) 
OCP consumption was found in 41.2% of females 
(21/51). Short term consumption was found in 72.4% 
of females with CVT who had taken OCP (21/29); 
95.2% of this latter group used LD (20/29 LD and 
1/29 HD respectively). Among females on short term 
OCP, Ramadan and Hadj religious months were the 
reason for using short term OCP in 85.7% (18/21) 
and 4.8% (1/21) respectively. Distribution of CVT in 
Ramadan was significantly higher than other months 
in the females (χ2 = 14.7, P = 0.001). 63.6% of our 
males with CVT had uncertain etiology despite com-
plete diagnostic investigations. 
Discussion  
In developed countries, the role of OCP is more im-
portant.1,9 82.2 % of our CVT were seen in females 
and OCP was the causing factor in 56.8% of them. 
OCP consumption constituted 43% of CVT etiolo-
gies and found in 51% of females with CVT in Ta-
briz, north western Iran.10 In a French study on 134 
CVT patients, OCP was the only etiologic factor in 
10% of the cases, however OCP usage was also asso-
ciated with other conditions such as systemic lupus 
erythematosus (SLE) or Behcet disease in another 
10%.11 The detection of congenital thrombophilia 
should be systematic in CVT since it potentiates the 
risk of venous thrombosis associated with other con-
ditions, including OCP or puerperium.9,12 The use of 
OCP in carriers of thrombophilic abnormality exten-
sively increases the risk of CVT (Ods Ratio: 149).13 
De Bruijin et al reported a 30-fold increased risk of 
CVT in women with a combination of thrombophilic 
abnormalities and use of OCP compared with women 
without either risk factor.14 Increased levels of coagu-
lation factors 7, 8, 10, fibrinogen and prothrombin 
has been found in women using OCP, these findings 
are more common in women on OCP containing de-
sogestrol.15 LD is the usual type of OCP in Iranian 
drug market. Short term LD-OCP has an extremely 
important role in development of CVT in Iranian 
women. Since menstrual period prohibits Muslim 
women from entering the holy places during Hadj 
customs and disallows their fasting in Ramadan, they 
use short term OCP for a month in order to postpone 
menstruation and performing religious duties. At the 
other side, dehydarion during fasting in Ramadan fa-
cilitates development of CVT in females on OCP. 
This concept highlights the need for public awareness 
of this important complication of OCP in Muslim 
women especially during Ramadan month. 
           
Table 1. Etiologies of cerebral venous thrombosis in 62 Iranian patients 
Both genders (n = 62) 
(%) 
Males (n = 11) 
(%) 
Females (n = 51) 
(%) Etiology 
29-46.8 _ 29-56.8 Oral Copntraceptives 
18-29 1-9.1 17-33.3 Dehydration 
9-13.8 2-18.2 7-13.7 Hypercoagulable state 
2-3.2 _ 2-3.9 Postpartum 
3-4.8 _ 3-5.9 Pregnancy 
2-3.2 _ 2-3.9 Other Medications 
2-3.2 1-9.1 1-1.9 Otitis 
1-1.6 _ 1-1.9 Meningioma 
1-1.6 _ 1-1.9 Lupus Erythematosus 
18-29 _ 18-35.3 Multiple 
15-24.2 7-63.6 8-15.7 Uncertain 
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